{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:30:37Z","timestamp":1791898237579,"version":"4.3.4"},"reference-count":101,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Center of Innovation Program from Japan Science and Technology Agency (JST)","doi-asserted-by":"publisher","award":["JPMJCE1304"],"award-info":[{"award-number":["JPMJCE1304"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Center of Innovation Program from Japan Science and Technology Agency (JST)","doi-asserted-by":"publisher","award":["JP21tm0424221"],"award-info":[{"award-number":["JP21tm0424221"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Center of Innovation Program from Japan Science and Technology Agency (JST)","doi-asserted-by":"publisher","award":["JP21zf0127004"],"award-info":[{"award-number":["JP21zf0127004"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Center of Innovation Program from Japan Science and Technology Agency (JST)","doi-asserted-by":"publisher","award":["JP22ek0410074"],"award-info":[{"award-number":["JP22ek0410074"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Center of Innovation Program from Japan Science and Technology Agency (JST)","doi-asserted-by":"publisher","award":["JP223fa627001"],"award-info":[{"award-number":["JP223fa627001"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Center of Innovation Program from Japan Science and Technology Agency (JST)","doi-asserted-by":"publisher","award":["JP233fa627001"],"award-info":[{"award-number":["JP233fa627001"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Center of Innovation Program from Japan Science and Technology Agency (JST)","doi-asserted-by":"publisher","award":["JP23gm1810005"],"award-info":[{"award-number":["JP23gm1810005"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Center of Innovation Program from Japan Science and Technology Agency (JST)","doi-asserted-by":"publisher","award":["JP22K08559"],"award-info":[{"award-number":["JP22K08559"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["JPMJCE1304"],"award-info":[{"award-number":["JPMJCE1304"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["JP21tm0424221"],"award-info":[{"award-number":["JP21tm0424221"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["JP21zf0127004"],"award-info":[{"award-number":["JP21zf0127004"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["JP22ek0410074"],"award-info":[{"award-number":["JP22ek0410074"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["JP223fa627001"],"award-info":[{"award-number":["JP223fa627001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["JP233fa627001"],"award-info":[{"award-number":["JP233fa627001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["JP23gm1810005"],"award-info":[{"award-number":["JP23gm1810005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["JP22K08559"],"award-info":[{"award-number":["JP22K08559"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the AMED","doi-asserted-by":"publisher","award":["JPMJCE1304"],"award-info":[{"award-number":["JPMJCE1304"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the AMED","doi-asserted-by":"publisher","award":["JP21tm0424221"],"award-info":[{"award-number":["JP21tm0424221"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the AMED","doi-asserted-by":"publisher","award":["JP21zf0127004"],"award-info":[{"award-number":["JP21zf0127004"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the AMED","doi-asserted-by":"publisher","award":["JP22ek0410074"],"award-info":[{"award-number":["JP22ek0410074"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the AMED","doi-asserted-by":"publisher","award":["JP223fa627001"],"award-info":[{"award-number":["JP223fa627001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the AMED","doi-asserted-by":"publisher","award":["JP233fa627001"],"award-info":[{"award-number":["JP233fa627001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the AMED","doi-asserted-by":"publisher","award":["JP23gm1810005"],"award-info":[{"award-number":["JP23gm1810005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Ministry of Education, Culture, Sports, and the AMED","doi-asserted-by":"publisher","award":["JP22K08559"],"award-info":[{"award-number":["JP22K08559"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C)","doi-asserted-by":"publisher","award":["JPMJCE1304"],"award-info":[{"award-number":["JPMJCE1304"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C)","doi-asserted-by":"publisher","award":["JP21tm0424221"],"award-info":[{"award-number":["JP21tm0424221"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C)","doi-asserted-by":"publisher","award":["JP21zf0127004"],"award-info":[{"award-number":["JP21zf0127004"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C)","doi-asserted-by":"publisher","award":["JP22ek0410074"],"award-info":[{"award-number":["JP22ek0410074"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C)","doi-asserted-by":"publisher","award":["JP223fa627001"],"award-info":[{"award-number":["JP223fa627001"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C)","doi-asserted-by":"publisher","award":["JP233fa627001"],"award-info":[{"award-number":["JP233fa627001"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C)","doi-asserted-by":"publisher","award":["JP23gm1810005"],"award-info":[{"award-number":["JP23gm1810005"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C)","doi-asserted-by":"publisher","award":["JP22K08559"],"award-info":[{"award-number":["JP22K08559"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical manifestations that can lead to severe organ damage. The complex pathophysiology of SLE makes treatment selection difficult. This review examines the current evidence for biological therapies in SLE, including the anti-B cell activating factor antibody belimumab; the type I interferon receptor antagonist anifrolumab; the novel calcineurin inhibitor voclosporin; and rituximab, which targets CD20 on B cells. We also describe emerging therapies, including novel agents in development and CD19-directed chimeric antigen receptor (CAR) T cell therapy, which has shown promise in early clinical experience. Recent advances in biomarker research, including interferon signatures and transcriptomic profiles, may facilitate patient stratification and treatment selection. This review offers insights into current and future treatment strategies for patients with SLE by analyzing clinical trial results and recent immunological findings.<\/jats:p>","DOI":"10.3390\/ijms26030929","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T09:01:13Z","timestamp":1737622873000},"page":"929","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Advances in Targeted Therapy for Systemic Lupus Erythematosus: Current Treatments and Novel Approaches"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8410-3151","authenticated-orcid":false,"given":"Kazusa","family":"Saegusa","sequence":"first","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-6157","authenticated-orcid":false,"given":"Yumi","family":"Tsuchida","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5890-3606","authenticated-orcid":false,"given":"Toshihiko","family":"Komai","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-5254","authenticated-orcid":false,"given":"Keishi","family":"Fujio","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41590-024-01898-7","article-title":"The immunology of systemic lupus erythematosus","volume":"25","author":"Tsokos","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Hanly","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.42920","article-title":"Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: A systematic review and meta-analysis of the control arms of randomized controlled trials","volume":"76","author":"Prokop","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/rheumatology\/keaa267","article-title":"Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls","volume":"60","author":"Lalmohamed","year":"2021","journal-title":"Rheumatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3899\/jrheum.160214","article-title":"Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: Findings from a 12-year longitudinal study","volume":"45","author":"Chen","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/09612033231160969","article-title":"Estimating glucocorticoid-related morbidity in lupus nephritis using the glucocorticoid toxicity index","volume":"32","author":"Usiskin","year":"2023","journal-title":"Lupus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group (2024). KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int., 105, S1\u2013S69.","DOI":"10.1016\/j.kint.2023.09.002"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: High disease activity predictors of response","volume":"71","author":"Petri","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e000710","DOI":"10.1136\/lupus-2022-000710","article-title":"Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study","volume":"9","author":"Hunnicutt","year":"2022","journal-title":"Lupus Sci. Med."},{"key":"ref_16","first-page":"CD010668","article-title":"Belimumab for systemic lupus erythematosus","volume":"2","author":"Singh","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.41253","article-title":"Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real-life setting","volume":"72","author":"Gatto","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/mr\/roac140","article-title":"Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2020.1812201","article-title":"Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: An overview from clinical trials","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/rheumatology\/kev387","article-title":"From BILAG to BILAG-based combined lupus assessment-30 years on","volume":"55","author":"Murphy","year":"2016","journal-title":"Rheumatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ard-2022-222748","article-title":"Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus","volume":"82","author":"Morand","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e000284","DOI":"10.1136\/lupus-2018-000284","article-title":"Anifrolumab effects on rash and arthritis: Impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus","volume":"5","author":"Merrill","year":"2018","journal-title":"Lupus Sci. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/art.41598","article-title":"Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: Results of a phase II open-label extension study","volume":"73","author":"Chatham","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/rheumatology\/kex395","article-title":"Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: Results from the British Isles Lupus Assessment Group Biologics Register","volume":"57","author":"McCarthy","year":"2018","journal-title":"Rheumatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.24999","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults","volume":"93","author":"Serris","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Malkiel","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(22)00332-0","article-title":"Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: An exploratory analysis of a randomised controlled trial","volume":"5","author":"Shipa","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/ard-2024-225686","article-title":"Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: The phase 3, randomised, placebo-controlled BLISS-BELIEVE study","volume":"83","author":"Aranow","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1093\/rheumatology\/keac150","article-title":"Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab","volume":"61","author":"Arnold","year":"2022","journal-title":"Rheumatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti\u2013CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology"},{"key":"ref_43","unstructured":"(2024, December 21). Megan Clowse, David Isenberg, Joan Merrill, Thomas D\u00f6rner, Michelle Petri, Edward Vital, Eric Morand, Teri Jimenez, Stephen Brookes, Janine Gaiha-Rohrbach, Christophe Martin, Annette Nelde and Christian Stach. Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial. ACR Convergence 2024. Available online: https:\/\/acrabstracts.org\/abstract\/dapirolizumab-pegol-demonstrated-significant-improvement-in-systemic-lupus-erythematosus-disease-activity-efficacy-and-safety-results-of-a-phase-3-trial\/."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: Results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","unstructured":"(2025, January 16). Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus: A Randomise Prospective Study. Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05339217."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_47","first-page":"1518","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: A phase 2 randomized controlled trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: A phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Arriens, C., Askanase, A., Furie, R., Morand, E.F., Van Vollenhoven, R., Connors, K., Davey, M., Delev, N., Shah, V., and Stevens, A. (2023). Ab0530 design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (tyk2) inhibitor, in patients with active systemic lupus erythematosus. Scientific Abstracts, European League Against Rheumatism.","DOI":"10.1136\/annrheumdis-2023-eular.3881"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_52","unstructured":"(2025, January 16). A Prospective, Single-Center Study of Comparing the Efficacy and Safety of Human Umbilical Cord Mesenchymal Stem Cells and Low-dose IL-2 in the Treatment of Lupus Nephritis. Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05631717."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: Results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"Kalunian","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_55","first-page":"e17198","article-title":"Secukinumab on refractory lupus nephritis","volume":"13","author":"Costa","year":"2021","journal-title":"Cureus"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/24725625.2020.1717741","article-title":"Treatment of psoriatic arthritis complicated by systemic lupus erythematosus with the IL-17 blocker secukinumab and an analysis of the serum cytokine profile","volume":"4","author":"Sato","year":"2020","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_57","unstructured":"(2025, January 16). A Pilot Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus. Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03866317."},{"key":"ref_58","unstructured":"(2025, January 16). A Two-year, Phase III Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis. Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04181762?cond=Systemic%20Lupus%20Erythematosus&intr=Secukinumab&rank=3."},{"key":"ref_59","unstructured":"(2025, January 16). A Three-year, Open-Label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability in Patients with Active Lupus Nephritis. Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05232864."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1093\/rheumatology\/keab918","article-title":"Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis","volume":"61","author":"Oakley","year":"2022","journal-title":"Rheumatology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"S753","DOI":"10.1097\/RHU.0000000000001511","article-title":"Secukinumab-induced lupus erythematosus: A case report and literature review","volume":"27","author":"Kaler","year":"2021","journal-title":"J. Clin. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014A case series with follow-up","volume":"390","author":"Taubmann","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: A phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17474086.2024.2353751","article-title":"Elranatamab vs. teclistamab: Battle of the BCMA bispecifics in relapsed\/refractory multiple myeloma","volume":"17","author":"Moore","year":"2024","journal-title":"Expert Rev. Hematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat. Med."},{"key":"ref_73","unstructured":"(2024, December 16). A Study of CLN-978, a Subcutaneously Administered CD19-Directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus. Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06613360."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e007398","DOI":"10.1136\/jitc-2023-007398","article-title":"CLN-978, a novel half-life extended CD19\/CD3\/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression","volume":"11","author":"Meetze","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41584-023-00948-y","article-title":"Precision medicine in systemic lupus erythematosus","volume":"19","author":"Fasano","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJMoa0707865","article-title":"Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX","volume":"358","author":"Hom","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ng.79","article-title":"Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus","volume":"40","author":"Kozyrev","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/91070","article-title":"Mutation of DNASE1 in people with systemic lupus erythematosus","volume":"28","author":"Yasutomo","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/ng.975","article-title":"Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus","volume":"43","author":"Sunker","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1681\/ASN.2013050446","article-title":"Lupus nephritis susceptibility loci in women with systemic lupus erythematosus","volume":"25","author":"Chung","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000045475","article-title":"Enhanced Hyaluronan Synthesis in the MRL-Faslpr Kidney: Role of Cytokines","volume":"83","author":"Feusi","year":"1999","journal-title":"Nephron"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"J\u00e4rvinen, T.M., Hellquist, A., Koskenmies, S., Einarsdottir, E., Panelius, J., Hasan, T., Julkunen, H., Padyukov, L., Kvarnstr\u00f6m, M., and Wahren-Herlenius, M. (2010). Polymorphisms of the ITGAM gene confer higher risk of discoid cutaneous than of systemic lupus erythematosus. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0014212"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Taylor, K.E., Chung, S.A., Graham, R.R., Ortmann, W.A., Lee, A.T., Langefeld, C.D., Jacob, C.O., Kamboh, M.I., Alarc\u00f3n-Riquelme, M.E., and Tsao, B.P. (2011). Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet., 7.","DOI":"10.1371\/journal.pgen.1001311"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3899\/jrheum.150884","article-title":"Genetic variants that are associated with neuropsychiatric systemic lupus erythematosus","volume":"43","author":"Ho","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"eabf1970","DOI":"10.1126\/science.abf1970","article-title":"Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus","volume":"376","author":"Perez","year":"2022","journal-title":"Science"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Adams, D.E., and Shao, W.H. (2022). Epigenetic alterations in immune cells of systemic lupus erythematosus and therapeutic implications. Cells, 11.","DOI":"10.3390\/cells11030506"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Perez-Hernandez, J., Forner, M.J., Pinto, C., Chaves, F.J., Cortes, R., and Redon, J. (2015). Increased urinary exosomal MicroRNAs in patients with systemic lupus erythematosus. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138618"},{"key":"ref_88","first-page":"4067","article-title":"Increased expression of hub gene CXCL10 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus","volume":"18","author":"Zhang","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1006\/cyto.2000.0757","article-title":"Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus","volume":"12","author":"Narumi","year":"2000","journal-title":"Cytokine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"v12","DOI":"10.1093\/rheumatology\/keaa484","article-title":"New biomarkers in SLE: From bench to bedside","volume":"59","author":"Capecchi","year":"2020","journal-title":"Rheumatology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/art.22451","article-title":"Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus","volume":"56","author":"Llorente","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/annrheumdis-2018-213497","article-title":"Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome","volume":"77","author":"Mertens","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13075-018-1649-1","article-title":"The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus","volume":"20","author":"Oliveira","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e000063","DOI":"10.1136\/lupus-2014-000063","article-title":"BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year","volume":"2","author":"Zollars","year":"2015","journal-title":"Lupus Sci. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00393-016-0109-z","article-title":"Urinary MCP-1 as a biomarker for lupus nephritis: A meta-analysis","volume":"76","author":"Lee","year":"2017","journal-title":"Z. Rheumatol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Xuejing, Z., Jiazhen, T., Jun, L., Xiangqing, X., Shuguang, Y., and Fuyou, L. (2012). Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J. Biomed. Biotechnol., 2012.","DOI":"10.1155\/2012\/359647"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/rheumatology\/kep468","article-title":"Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis","volume":"49","author":"Rubinstein","year":"2010","journal-title":"Rheumatology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/1756-185X.13689","article-title":"Serum phosphatidylserine-specific phospholipase A1 as a novel biomarker for monitoring systemic lupus erythematosus disease activity","volume":"22","author":"Sawada","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1016\/j.cell.2022.07.021","article-title":"Distinct transcriptome architectures underlying lupus establishment and exacerbation","volume":"185","author":"Nakano","year":"2022","journal-title":"Cell"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1016\/S2665-9913(20)30168-5","article-title":"Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: Patient stratification using a machine-learning approach","volume":"2","author":"Robinson","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.cell.2021.03.056","article-title":"Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases","volume":"184","author":"Ota","year":"2021","journal-title":"Cell"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/929\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:34:08Z","timestamp":1759919648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":101,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ijms26030929"],"URL":"https:\/\/doi.org\/10.3390\/ijms26030929","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}